In this edition of #Nephstats, we look at Number Needed to Treat (NNT), a controversial topic creates ripples and roars on social media amongst stat savvy physicians, epidemiologists and biostatisticians. This seems like such a simple and easy number to make sense of a trial’s importance - what could be controversial or wrong about it?

How do you understand the inverted world of non-inferiority? Manasi Bapat breaks it down for us here

She’s back: A stats explainer of statistical modelling, goodness of fit and the Bayes information criterion from Manasi Bapat.

When a study is negative the work is not done. Time to separate a negative trial from an underpowered one. Learn how to think about this with Manasi Bapat.

Propensity scores…what’s up with that?

Multiple testing and the Bonferroni - NSMC intern and NephJC stats explainer Manasi Bapat breaks it down for you in this post. 

Manasi deconstructs pragmatic trials for us. How are they different compared to efficacy & explanatory trials? 

Manasi Bapat takes you behind the scenes to explain the need for doing sensitivity analyses

We begin a series of occasional commentary on the methods underlying the research being discussed. This edition: the 2 x 2 factorial designs. 

The summary is not enough. Check out these tweetorials on

• Why did we lose the ability to handle excess uric acid?

• What is mendelian randomization and what does it tell us here?

Dr Singh provides his view on this week’s paper in a tight tweetorial.

Some cases of ADTKD are due to mutations of the MUC-1 gene, one mutation is a frame shift mutation that results in a premature stop codon. which results in accumulation of the abnormally short, and toxic protein MUC-1 fs . The researchers found a small protein, BRD4780, that reroute MUC-1fs to lysosomes, preventing proteinopathy and possibly altering the natural history of the disease.